COMMUNIQUÉS West-GlobeNewswire

Apyx Medical Corporation Reports Fourth Quarter and Full Year 2025 Financial Results
10/03/2026
Reported record total revenue of $19.2 million in the fourth quarter of 2025 Scaling U.S. commercial launch of AYON Body Contouring System ™ (AYON) to meet strong market demand Expect FY2026 total revenue in the range [...]
Rapport Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
10/03/2026
RAP-219’s lead program demonstrated robust and consistent activity in patients with focal onset seizures (FOS) in Phase 2a trial; initiation of Phase 3 program expected in the second quarter of 2026 RAP- 219 epilepsy [...]
Legend Biotech Reports Fourth Quarter and Full Year 2025 Results and Recent Highlights
10/03/2026
CARVYKTI ® (ciltacabtagene autoleucel; cilta-cel) net trade sales of approximately $555 million and $1.9 billion for the fourth quarter and full year 2025, respectively Surpassed milestone of more than 10,000 patients [...]
Satellos Presents Interim SAT-3247 Clinical and Biomarker Data in Duchenne Muscular Dystrophy at the 2026 MDA Clinical & Scientific Conference
10/03/2026
Interim observations from the Phase 2 TRAILHEAD study show continued improvement in handgrip strength, overall stability of elbow and shoulder strength in new dynamometry measurements Greater improvements in strength [...]
CRISPR Therapeutics Announces Proposed Convertible Senior Notes Offering
10/03/2026
ZUG, Switzerland and BOSTON, March 10, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics AG (Nasdaq: CRSP) (the “Company”) today announced its intention to offer, subject to market conditions and other factors, $350 million [...]
Guidelight Names Kelly Jones as Chief Growth Officer
10/03/2026
Mission-driven behavioral healthcare leader brings deep expertise in scaling access to high-quality, evidence-based care BOSTON, March 10, 2026 (GLOBE NEWSWIRE) -- Guidelight, a leader in evidence-based mental health [...]
Cullinan Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results
10/03/2026
Initial clinical data for CLN-978 in SLE and RA confirmed for Q2 2026; repeat dosing data in RA confirmed for Q3 2026 Zipalertinib rolling NDA submission completed; enrollment of REZILIENT3 frontline study completed [...]
Vireo Growth Inc. to Release Fourth Quarter and Full Year 2025 Results on March 17, 2026
10/03/2026
MINNEAPOLIS, March 10, 2026 (GLOBE NEWSWIRE) -- Vireo Growth Inc. ("Vireo" or the "Company") (CSE: VREO; OTCQX: VREOF), today announced that it will release its financial results for its fourth quarter and full fiscal [...]
BioNTech Announces Fourth Quarter and Full Year 2025 Financial Results and Corporate Update
10/03/2026
BioNTech on track for a catalyst-rich year with six late-stage data readouts expected across immunomodulators, antibody-drug conjugates and mRNA cancer immunotherapies Increased focus on PD-L1 1 /VEGF-A bispecific [...]
BioNTech and Co-Founders Announce Plan to Pursue Next-Generation mRNA Innovations in Co-Founders-Led New Company as BioNTech Advances Toward Becoming a Multi-Product Company by 2030
10/03/2026
BioNTech continues to sharpen its strategic focus on the growing late-stage clinical pipeline spanning immunomodulator, ADC and mRNA candidates BioNTech co-founders Ugur Sahin and Özlem Türeci will establish an [...]
EVAA.AI Expands to Integrate with Multiple Eye Care EHR Systems
10/03/2026
Eye care practices can now access EVAA’s AI-powered billing automation and clinical documentation tools without changing their existing EHR system PORTLAND, Ore., March 10, 2026 (GLOBE NEWSWIRE) -- EVAA.AI , part of the [...]
BPL-003 Phase 3 Program Initiation on Track for Q2 2026 Following Successful FDA End-of-Phase 2 Meeting; AtaiBeckley Highlights Key Pipeline Milestones at 2026 Investor Day
10/03/2026
BPL‑003 holds Breakthrough Therapy Designation and is supported by positive Phase 2b results in treatment-resistant depression Cash runway reaffirmed through the planned early-2029 topline readouts from both parallel [...]
MiNK Therapeutics Announces Collaboration with C-Further to Advance PRAME-Targeted iNKT Cell Therapy for Pediatric Cancers
10/03/2026
Selected as a C-Further program with up to ~$1.1 million in non-dilutive, aggregate payments to advance IND-enabling development, with potential for meaningful double-digit downstream commercial revenue participation [...]
TECVAYLI®▼ (teclistamab) monotherapy application submitted to the EMA for relapsed/refractory multiple myeloma after at least one prior therapy
10/03/2026
Application supported by Phase 3 data reinforcing teclistamab regimens as a potential standard of care after at least one prior therapy 1 Teclistamab monotherapy delivered superior progression-free survival and overall [...]
EnteroBiotix Announces Completion of Enrolment in Phase 2a Trial Evaluating EBX-102-02 Prior to Allogeneic Stem Cell Transplantation
10/03/2026
GLASGOW, United Kingdom, March 10, 2026 (GLOBE NEWSWIRE) -- EnteroBiotix, a clinical-stage biopharmaceutical company developing best-in-class microbiome therapies, today announced that the investigator-initiated Phase [...]
Tenax Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
10/03/2026
Achieved randomization target of 230 patients in LEVEL study, topline data expected in third quarter of 2026 Initiated global Phase 3 LEVEL-2 clinical trial and opened long-term OLE study for patients to remain on drug [...]
Kuros Biosciences delivers 72% year-over-year sales growth, reaching USD 146.1 million for 2025
10/03/2026
Ad-hoc announcement pursuant to Article 53 of the SIX listing rules Kuros Biosciences delivers 72% year-over-year sales growth, reaching USD 146.1 million for 2025 Financial Highlights Total Medical Device sales rose by [...]
Santhera Appoints Marc Clausse as Chief Commercial Officer to Lead Next Phase of Growth
10/03/2026
Pratteln, Switzerland, March 10, 2026 – Santhera Pharmaceuticals (SIX: SANN) announces the appointment of Marc Clausse as Chief Commercial Officer (CCO), effective June 1, 2026. He succeeds Geert Jan van Daal, who will [...]
Idorsia expands QUVIVIQ’s global footprint through new partnership with Pharmalink
10/03/2026
Idorsia and Pharmalink enter into an exclusive distribution and commercialization agreement for QUVIVIQ ™ (daridorexant) in the United Arab Emirates (UAE), Kuwait, Qatar, Oman, and Bahrain Allschwil, Switzerland – March [...]

Pages